ACG Group, a provider of products and services for capsule and tablet manufacturing, and Applied DNA Sciences, a Stony Brook, New York-headquartered molecular-based authentication service provider, have signed a memorandum of understanding (MoU) to allow ACG to use Applied DNA’s SigNature molecular tagging and authentication technologies to develop molecularly tagged empty hard-shell capsules. The MoU is expected to be followed by a definitive agreement.

The development of molecularly tagged empty hard-shell capsules is expected to allow ACG’s customers to enhance the integrity of distribution channels. It is also expected to provide pharmaceutical companies with increased and assured capabilities when investigating suspected counterfeit medicines and help enhance patient and regulator confidence in pharmaceutical companies and their supply chains.

Applied DNA says its SigNature technology allows the embedding of a molecular tag into one or more capsule component materials. Each molecular tag can be formulated to specifically adhere tenaciously to a variety of substrates and is designed to allow for authentication at any point in the pharmaceutical supply chain.

Source: ACG Group